Evidence map›Paper›PMID 37899245›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis.

Yusei Tsukamoto, Yuya Ito, Yasushi Obase, Takahiro Takazono, Nana Nakada, Nobuyuki Ashizawa, Tatsuro Hirayama, Kazuaki Takeda, Shotaro Ide, Naoki Iwanaga and 7 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Describing the burden and characteristics ofBMJ open respiratory research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yusei TsukamotoDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Yuya ItoDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Yasushi ObaseDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Nana NakadaDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Nobuyuki AshizawaDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Tatsuro HirayamaDepartment of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Kazuaki TakedaDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Shotaro IdeDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Naoki IwanagaDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Masato TashiroDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Naoki HosogayaClinical Research Center, Nagasaki University Hosipital, Japan.
Susumu FukahoriDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Chizu FukushimaClinical Research Center, Nagasaki University Hosipital, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Japan.
Koichi IzumikawaDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Hospital, Japan.
Nagasaki University Hospital · JPNagasaki University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA) are diseases caused by Aspergillus infection, and CPA can develop from ABPA in some cases. We herein report a patient with CPA overlapping with ABPA. Serum cytokine levels were evaluated at 4 time points: the ABPA diagnosis, CPA diagnosis, 6 months after the start of voriconazole (VRCZ), and 12 months after re-administration of VRCZ. Interleukin (IL)-13 levels decreased upon glucocorticoid treatment, whereas IL-25 and IL-33 levels decreased rapidly with the initiation of antifungals. Early antifungal therapy may be important to control disease progression and prevent CPA overlap.

Indexed as

Aspergillosis, Allergic BronchopulmonaryCytokinesPulmonary AspergillosisVoriconazoleAntifungal AgentsChronic DiseaseHumansMaleMiddle AgedAntifungal AgentsCytokinesVoriconazoleallergic bronchopulmonary aspergillosis (ABPA)chronic pulmonary aspergillosis (CPA)IL-10IL-33

Identifiers

PMID37899245
PMCPMC11189703
OpenAlexW4387954062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.